Treating to target in type 2 diabetes: the BEGIN trial programme.

@article{Wangnoo2014TreatingTT,
  title={Treating to target in type 2 diabetes: the BEGIN trial programme.},
  author={Subhash Kumar Wangnoo and Subhankar Chowdhury and Paturi Vishnupriya Rao},
  journal={The Journal of the Association of Physicians of India},
  year={2014},
  volume={62 1 Suppl},
  pages={21-6}
}
Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. The insulin degludec and insulin degludec/insulin aspart clinical trial programme was truly global, involving 40 different countries and encompassing a multitude of ethnic populations. It is the largest insulin development clinical trial programme on record--with more than 11,000 patients included worldwide. It includes two main components: BEGIN (insulin degludec studied across the spectrum of diabetes… CONTINUE READING
2 Citations
22 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Effect of ultra-long-acting insulin degludec versus sitagliptin addition in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obesity Metab 2013;15:760-6

  • A Philis-Tsimikas, S Del Prato, I Satman
  • 2013

Effect of ultralong - acting insulin degludec versus sitagliptin addition in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

  • A Philis-Tsimikas, S DelPrato, I Satman
  • Diabetes Obesity Metab
  • 2013

Similar Papers

Loading similar papers…